Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect additional safety information on abiraterone acetate
administered with prednisone to patients with metastatic castration-resistant prostate cancer
(CRPC).
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.